Mirgi (Ethinylestradiol, Etonogestrel)

Ethinylestradiol/Etonogestrel, the active ingredients in Mirgi, are a combined estrogen‑progestogen presented as a vaginal ring for vaginal use. The ring releases a steady low dose of hormones over three weeks, maintaining plasma levels sufficient to prevent ovulation and to create cervical mucus changes that impede sperm penetration. It provides reversible contraception for women of childbearing age.

GNH USA supplies Mirgi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirgi, a combined estrogen‑progestogen vaginal ring, is indicated for hormonal contraception and related menstrual management.

- Contraception: provides effective, reversible birth control for women of reproductive age. - Menstrual symptom control: reduces dysmenorrhea and heavy menstrual bleeding associated with hormonal cycles. - Cycle regulation: helps establish a predictable menstrual cycle pattern in women using hormonal contraception.

Adverse reactions reported with Mirgi are categorized by frequency.

Common Side Effects: - Vaginal irritation or discharge: mild irritation or increased discharge at the insertion site. - Headache: transient mild to moderate headaches. - Nausea: occasional stomach upset. - Breast tenderness: mild swelling or discomfort. - Mood changes: irritability or mood swings.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic adenoma: rare liver tumor. - Hypertension: significant increase in blood pressure. - Visual disturbances: sudden vision changes or loss.

Before prescribing Mirgi, clinicians should assess individual risk factors and counsel patients on safe use. - Pregnancy testing: confirm non‑pregnant status prior to initiation. - Smoking restriction: advise women over 35 to avoid smoking while using the ring. - Clotting disorders: review history of thromboembolic disease or thrombophilia. - Blood pressure monitoring: check baseline and periodic blood pressure. - Drug interaction review: evaluate concurrent medications that may affect hormone levels. - Store at ambient temperature: keep in original packaging, protect from moisture and excessive heat.

Mirgi may interact with other medicines that alter hormone metabolism or efficacy.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Rifampin or other rifamycins: can lower hormone levels. - St. John's wort: potent enzyme inducer that may compromise contraception.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly reduce effectiveness. - Antifungal agents (e.g., ketoconazole, itraconazole): can increase hormone concentrations. - Antiretroviral drugs (e.g., protease inhibitors): may affect hormone metabolism and require monitoring.